Literature DB >> 31825850

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.

Angel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno, Justin Saco, Helena Escuin-Ordinas, Gabriel Abril Rodriguez, Jesse M Zaretsky, Lu Sun, Willy Hugo, Xiaoyan Wang, Giulia Parisi, Cristina Puig Saus, Davis Y Torrejon, Thomas G Graeber, Begonya Comin-Anduix, Siwen Hu-Lieskovan, Robert Damoiseaux, Roger S Lo, Antoni Ribas.   

Abstract

Entities:  

Year:  2019        PMID： 31825850     DOI： 10.1016/j.celrep.2019.11.113

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


× No keyword cloud information.
  29 in total

1.  HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer.

Authors:  Debarati Banik; Satish Noonepalle; Melissa Hadley; Erica Palmer; Maria Gracia-Hernandez; Christian Zevallos-Delgado; Namratta Manhas; Hayk Simonyan; Colin N Young; Anastas Popratiloff; Katherine B Chiappinelli; Rohan Fernandes; Eduardo M Sotomayor; Alejandro Villagra
Journal:  Cancer Res       Date:  2020-06-30       Impact factor: 12.701

2.  Upregulation of PD-L1 in Senescence and Aging.

Authors:  Angelique Onorati; Aaron P Havas; Brian Lin; Jayaraj Rajagopal; Payel Sen; Peter D Adams; Zhixun Dou
Journal:  Mol Cell Biol       Date:  2022-09-26       Impact factor: 5.069

3.  Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer.

Authors:  Karin Bauer; Anna S Berghoff; Matthias Preusser; Gerwin Heller; Christoph C Zielinski; Peter Valent; Thomas W Grunt
Journal:  Am J Cancer Res       Date:  2021-02-01       Impact factor: 6.166

4.  S1PR4 ablation reduces tumor growth and improves chemotherapy via CD8+ T cell expansion.

Authors:  Catherine Olesch; Evelyn Sirait-Fischer; Matthias Berkefeld; Annika F Fink; Rosa M Susen; Birgit Ritter; Birgitta E Michels; Dieter Steinhilber; Florian R Greten; Rajkumar Savai; Kazuhiko Takeda; Bernhard Brüne; Andreas Weigert
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 19.456

Review 5.  Cytokine and Chemokine Signals of T-Cell Exclusion in Tumors.

Authors:  Yu Zhang; Xin-Yuan Guan; Peng Jiang
Journal:  Front Immunol       Date:  2020-12-14       Impact factor: 7.561

6.  Multi-omic analyses of hepatocellular carcinoma to determine immunological characteristics and key nodes in gene-expression network.

Authors:  Zhihui Wang; Shuijun Zhang
Journal:  Biosci Rep       Date:  2021-07-30       Impact factor: 3.840

7.  PD-L1 upregulation is associated with activation of the DNA double-strand break repair pathway in patients with colitic cancer.

Authors:  Naoya Ozawa; Takehiko Yokobori; Katsuya Osone; Chika Katayama; Kunihiko Suga; Chika Komine; Yuta Shibasaki; Takuya Shiraishi; Takuhisa Okada; Ryuji Kato; Hiroomi Ogawa; Akihiko Sano; Makoto Sakai; Makoto Sohda; Hitoshi Ojima; Tatsuya Miyazaki; Yoko Motegi; Munenori Ide; Takashi Yao; Hiroyuki Kuwano; Ken Shirabe; Hiroshi Saeki
Journal:  Sci Rep       Date:  2021-06-22       Impact factor: 4.379

Review 8.  Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1.

Authors:  Hao Cai; Yichi Zhang; Jian Wang; Jinyang Gu
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

9.  Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma.

Authors:  Qianhui Gu; Jing Li; Zhuolin Chen; Jie Zhang; Hui Shen; Xiaobing Miao; Ying Zhou; Xiaohong Xu; Song He
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

Review 10.  Biomarkers of immunotherapy in non-small cell lung cancer.

Authors:  Lingling Wang; Yue Hu; Shengchao Wang; Jiali Shen; Xiaochen Wang
Journal:  Oncol Lett       Date:  2020-08-20       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.